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Introduction
Temporomandibular disorders (TMD) are 
the second most common cause (after dental 
pain) of orofacial pain, characterised by pain 
in the temporomandibular joint area and in 
the facial muscles. Apart from pain, patients 
may experience other signs and symptoms, 
such as clicking of the joint and restricted 
mouth-opening. Around 5% to 12% of the 
population have TMD symptoms to some degree, 
varying by age group and gender.1 One of the most 
common ways in which dentists, particularly in 
primary care, manage symptomatic TMD is the 
provision of oral splints.2
Splints are also provided to help manage 
tooth wear caused by bruxism. The prevalence 
of bruxism ranges from 8% to 31% within the 
general population,3 and it is estimated globally 
that sleep bruxism affects 16%, and awake 
bruxism 24%, of the adult population.4
There is continuing debate about the exact 
mechanism of action of oral splints. Mechanisms 
include: muscle relaxation/habit-breaking for 
patients with increased parafunctional or muscle-
tightening habits; protection of teeth and jaws, 
particularly where teeth clenching and grinding 
may lead to damage of teeth; normalising 
periodontal ligament proprioception, by utilising 
a splint to spread the forces placed on individual 
teeth; and repositioning of the jaws and condyles 
into centric relation.
This systematic review arose from an 
National Institute for Health Research Health 
Technology Assessment call addressing the 
research question: ‘What is the clinical and 
cost-effectiveness of prefabricated oral splints 
and custom-made splints for the treatment of 
orofacial symptoms?’ (in press). This research 
presents part of this review, looking at whether 
oral splints are effective in reducing orofacial 
symptoms (primarily pain) and when they are 
indicated to prevent tooth wear.
Methods
We undertook the review using Cochrane 
methods,5 which are described in greater detail 
elsewhere (in press).
This systematic review comprehensively summarised 
the best available evidence from randomised 
controlled trials on the effects of oral splints for 
temporomandibular disorders (TMD) and bruxism.
There is no evidence to support the use of oral splints 
for either condition based on the results found.
For TMD patients, sensitivity analyses were 
conducted to explore the effects of differences in: 
1) diagnostic criteria; 2) splint types; and 3) outcome 
measures used and reported. There were no 
differences in the results based on these factors.
Key points
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Eligibility criteria
Randomised controlled trials were included 
(crossover studies were excluded as deemed 
inappropriate). We included children (over 
11 years old) and adults who had either TMD or 
bruxism, in either primary or secondary care.
We included trials where any type of splint 
was compared with a non-splint group. 
This group also included watchful waiting 
or minimal treatment (advice/counselling, 
education or self-performed exercises).
The primary outcomes were pain and 
harms. For bruxism patients, tooth wear 
was also considered a primary outcome. 
Secondary outcomes included clicking of the 
temporomandibular joint, change in restricted 
mouth opening, frequency of headaches and 
reduced quality of life. Patient satisfaction 
and adherence to treatment were collected 
whenever possible. For bruxism, the index 
and frequency of bruxism activity was also to 
be recorded.
Follow-up periods for the outcome data 
were divided into short-term follow-up (0 to 
3 months), medium-term (>3 to 6 months), 
or long-term (>6 to 12 months).
Search methods for identification of 
studies
An information specialist developed a search 
strategy (see online-only Supplementary 
Appendix  1) and conducted the literature 
searches on 1 October 2018. They were 
undertaken without restrictions on language 
or date of publication.
The following databases were searched: 
Cochrane Central Register of Controlled 
Trials (CENTRAL) in the Cochrane Library, 
MEDLINE Ovid, Embase Ovid, and CINAHL 
EBSCO. Unpublished data were sought via 
searches of the US National Institutes of Health 
trials register (ClinicalTrials.gov) and the WHO 
International Clinical Trials Registry Platform. 
Conference proceedings were searched via 
Embase and the Web of Science. Abstracts of 
dissertations and theses were searched via the 
Proquest database. Additional grey literature 
was sourced through the American Academy 
of Dental Sleep Medicine (AADSM; http://
www.aadsm.org/) website. The International 
Association of Dental Research (IADR) annual 
conference abstracts were searched via the 
IADR website.
Selection of studies and data extraction
Two review authors independently assessed 
studies retrieved by the searches for eligibility. 
Disagreements on study eligibility were 
resolved through discussion and consensus. If 
necessary, a third review author was consulted. 
Two review authors independently extracted 
the following data from the included trials: 
location/setting, type of provider, number 
of centres, recruitment period, trials registry 
ID, inclusion/exclusion criteria, demographic 
information, presenting condition and 
severity, type of splint, details of comparator, 
outcomes reported (including method and 
time of assessment), details of sample size 
calculations, funding sources and declarations/
conflicts of interest.
Assessment of risk of bias in included 
studies
The assessment of risk of bias was done 
independently and in duplicate, using the 
Cochrane risk of bias tool.5 The following 
domains were assessed: sequence generation; 
allocation concealment; blinding of 
participants and personnel; blinding of 
outcome assessors; incomplete outcome data; 
selective outcome reporting; and other bias. 
The overall risk of bias of individual studies 
was categorised as: low (plausible bias unlikely 
to seriously alter the results), if all domains 
were at low risk of bias; unclear (plausible bias 
that raises some doubt about the results), if one 
or more domains had an unclear risk of bias; 
or high, if one or more domains had a high 
risk of bias.
Statistical methods
For continuous outcomes, we used the means 
and standard deviations reported in the trials 
to express the estimate of effect as mean 
difference with 95% confidence interval 
(CI). If different scales were reported, we 
used standardised mean difference (SMD). 
For dichotomous outcomes, we expressed 
the estimate of effect as a risk ratio with 
95% CI.
We attempted to contact the author(s) of all 
included studies, where feasible, in the event 
of missing data. Missing standard deviations 
were estimated.5
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Fig. 1  Flow of studies through the review process
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We assessed heterogeneity statistically 
by using a Chi² test, where a P value of less 
than 0.1 indicates statistically significant 
heterogeneity. We quantified heterogeneity by 
using the I² statistic.
We combined mean differences (or 
SMDs) for continuous data, and risk ratios 
for dichotomous data, using random 
effects models.
Sensitivity analysis
For TMD patients, we undertook a sensitivity 
analysis restricted to trials where the 
inclusion criteria were based on, or could be 
clearly mapped to, one of the following sets 
of diagnostic criteria: Research Diagnostic 
Criteria for Temporomandibular disorders 
(RDC/TMD) guidelines;6 TMD (DC/TMD) 
guidelines;7 and American Association of 
Orofacial Pain (AAOP) guidelines.8 The 
outcome measures used and reported varied 
between studies; therefore, a sensitivity 
analysis was also carried out including only 
studies that measured pain at the time of 
assessment (current pain) on a 0 to 100 visual 
analogue or numerical rating scale. We also 
carried out sensitivity analysis based on splint 
types, restricting the analyses to studies using 
stabilisation splints.
Similarly, for bruxism patients, we planned 
to undertake a sensitivity analysis restricted to 
trials with a clear diagnosis of bruxism.9 The 
study should have used polysomnography 
(PSG) to diagnose the bruxism. There were 
insufficient trials to do this.
Presentation of main results
The certainty of the body of evidence was 
assessed following GRADE methods,10 
considering the overall risk of bias of included 
studies, the directness of the evidence, the 
inconsistency of the results, the precision of 
the estimates and the risk of publication bias. 
We categorised the certainty of the body of 
evidence for each of the main outcomes for 
each comparison as high, moderate, low or 
very low.
Results
Characteristics of included studies
Thirsty-seven studies were included (Fig. 1); 
34 on patients with TMD and two on patients 
with bruxism, with a further study on patients 
with both TMD and bruxism. All studies, 
with the exception of one, were conducted in 
universities or public hospitals/clinics.
For the studies evaluating the effectiveness 
of splints for people with TMD, the diagnostic 
criteria for TMD varied. However, the 
predominantly used criteria were the RDC,6 
used in 17 studies.11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,
27 The DC criteria7 were used in two studies,28,29 
and an additional three studies used criteria 
that approximated to the RDC (either by 
citing the instrument and/or their description 
matched a similar process).30,31,32 No studies 
used the AAOP criteria.8
The remaining studies used criteria that we 
had not pre-specified in our protocol or that 
were undefined/unclear:
• Three had used the Helkimo index33,34,35
• Two used arthrography36,37
• One used MRI38
• Six used diagnostic systems that were not 
possible to classify.39,40,41,42,43,44
The two studies45,46 examining the effects 
of splints on bruxism used the Lobbezzo 
et  al.9 criteria for likelihood of a bruxism 
diagnosis: ‘possible’ self-report of bruxism; 
‘probable’ clinical evidence of bruxism with or 
without self-report; and ‘definite’ defined by 
polysomnography. We classified both studies 
as examining ‘probable’ bruxism.
The study that examined bruxism with 
co-morbid TMD used the Fonseca index for 
TMD and examined ‘probable’ bruxism.47
Thirty-five studies compared splints 
against no splints for TMD patients. 
Ten of these studies used a no treatment 
control group.14,23,30,32,33,34,35,37,41,43 Twenty 
had a co-intervention in each arm, with 
13 having a ‘minimal’ co-intervention of 
usual treatment, counselling, information 
or exercise,11,12,13,15,16,17,18,19,21,22,25,26,36 while 
7 had a ‘non-minimal’ co-intervention of 
‘acuhealth’, manipulative and physical therapy, 
massage, Prozac, microcurrent electrical 
nerve stimulation, physical therapy with 
vapocoolant spray, arthrocentesis and sodium 
hyaluronate.27,28,29,39,40,44,47 The remaining six 
studies had minimal treatment controls: 
three were self-exercises,24,28,42 and three were 
information-based.20,27,31
One trial that has been referenced twice 
above27 had four arms with which we made 
two separate pairwise comparisons: 1) 
splint  +  co-intervention vs co-intervention 
alone; and 2) splint vs minimal treatment.
Nineteen studies used a stabilisation splint, 
14 of which were in the upper jaw (Michigan-
style splints),11,13,14,19,20,21,26,27,35,38,40,42,45,47 but not 
clearly reported in the other five.16,22,24,29,30
Seven studies compared more than one 
splint against no splint in this comparison, 
and were included twice in any meta-analysis 
as two separate pairwise comparisons.
For more details on the characteristics 
of the included studies, see online-only 
Supplementary Appendix 2.
Risk of bias
All 37 studies were assessed as being at high 
risk of bias overall due to a rating of high risk 
for at least one of the seven domains assessed 
(see Risk of bias summary in online-only 
Supplementary Appendix 3).
Ten studies were at low risk of selection bias 
because they adequately described methods 
used both to generate a truly random sequence 
and also to conceal the sequence from those 
involved in the randomisation process. The 
remaining studies were at unclear risk of 
selection bias as they had an unclear rating for 
either random sequence generation, allocation 
concealment, or both.
All studies, unavoidably, were at high risk 
of performance bias due to the comparison of 
splint against no splint. Thirty-five studies were 
at high risk of detection bias because patients 
knew their assigned group and also subjectively 
rated their own pain. The remaining two studies 
had a low risk of detection bias, the first being 
due to objective assessment of bruxism while 
the patients slept,46 and the second because 
no outcomes of this review were assessed and 
therefore this bias domain was irrelevant.47
Nine studies were at high risk of attrition bias 
due to high rates of attrition, large differences 
in attrition rates between groups, or both. The 
remaining six studies had an unclear risk of 
attrition bias due to poor reporting of numbers 
randomised or analysed.
Sixteen studies had problems with the way 
in which data were reported and were at high 
risk of reporting bias.
For other potential sources of bias, three 
studies were given a rating of high risk because 
outcomes were followed up at different times 
for the two groups. A further three studies were 
given an unclear rating for this domain because 
the reporting was poor and we were unable to 
properly assess them.
For more details on the risk of bias 
of the included studies, see online-only 
Supplementary Appendix 2.
Patients with TMD
There was consensus with clinicians and 
methodologists that 0  to 3 months was an 
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appropriate time point to use for the primary 
analysis of the data. The primary pain outcome 
was any continuous scale that was sensible 
to combine (for example, Visual Analogue 
Scale (VAS), Numerical Rating Scale (NRS), 
Characteristic Pain Intensity (CPI)).
Thirteen trials of 16 pairwise comparisons, 
all at high risk of bias and with 1,076 patients, 
contributed to the results for the main 
comparison at three months (Table 1). There 
was considerable heterogeneity and the overall 
SMD was -0.18 (95% CI -0.42 to 0.06). Using 
a rule of thumb for SMD effect estimates,5 
0.18 would be considered a small effect and, 
as this was not statistically significant, there 
is no evidence that oral splints reduce pain. 
Due to differences in splint type, the control 
group with no/minimal interventions and 
different types of TMD diagnoses between 
the individual studies, we were unable to 
investigate the heterogeneity any further. There 
were fewer studies and patients for the other 
time periods (>3  to 6 months: 2 trials, 160 
patients and >6 to 12 months: 2 trials, three 
pairwise comparisons, 246 patients) and the 
effect sizes also failed to demonstrate that oral 
splints reduced pain.
There was no evidence of adverse events 
associated with splints, but reporting was poor 
regarding this outcome.
There was also no evidence that splints 
reduced TMD clicking or increased mouth 
opening, or improved quality of life, at any 
of the time points measured (online-only 
Supplementary Appendix 4). The certainty of 
the evidence for all these other outcomes was 
assessed as very low.
For TMD patients, we planned to 
undertake a sensitivity analysis restricted to 
trials where the inclusion criteria were based 
on, or could be clearly mapped to, one of the 
sets of diagnostic criteria mentioned in the 
Methods section. For the primary analysis of 
splints versus no/minimal intervention at 0 to 
3 months (Table 1), there was no difference in 
Study or Subgroup
Splint Control
Weight Std.Mean Difference IV, Random, 95% CI
Std.Mean Difference IV,  
Random, 95% CIMean SD Total Mean SD Total
Conti 2015 (1) 9.23 22.5 12 37.62 22.5 9 3.8% -1.21 [-2.17, -0.26]
 
De Felicio 2010 (2) 14.56 8.14 10 13.6 9.49 10 4.2% 0.10 [-0.77, 0.98]
Giannakopoulos 2016 (3) 16.7 17.8 12 40.8 25 6 3.3% -1.13 [-2.19, -0.06]
Giannakopoulos 2016 (4) 30 27 12 40.8 25 6 3.6% -0.39 [-1.38, 0.60]
Haketa 2010 (5) 36.5 28.7 25 21.3 26.4 19 6.0% 0.54 [-0.07, 1.15]
Hasanoglu 2017 (1) 23 27.8 20 23.6 23.8 20 5.9% -0.02 [-0.64, 0.60]
Leeson 2007 (1) 41.1 26.2 62 38 28.1 63 8.1% 0.11 [-0.24, 0.46]
List 1992 (6) 18 17 34 28 18 22 6.5% -0.57 [-1.11, -0.02]
Nagata 2015 (7) 11.571 19.8797 96 8.268 15.6888 85 8.5% 0.18 [-0.11, 0.47]
Niemela 2012 (1) 34 32 39 40 26 37 7.2% -0.20 [-0.65, 0.25]
Nitecka-Buchta 2014 (1) 10 10.4 35 40 26 30 6.4% -1.54 [-2.10, -0.98]
Tatli 2017 (1) 20 19 40 15 17 40 7.3% 0.27 [-0.17, 0.72]
Truelove 2006 (8) 47.83 20 56 47.6 20 27 7.2% 0.01 [-0.45, 0.47]
Truelove 2006 (9) 45.08 20 54 47.6 20 27 7.1% -0.12 [-0.59, 0.34]
Yu 2016 (10) 20.5 8.7 42 21 11.7 42 7.4% -0.05 [-0.48, 0.38]
Yu 2016 (11) 19.7 9.3 42 20.2 8.9 42 7.4% -0.05 [-0.48, 0.37]
–
Total (95% CI) 591 485 100.0% -0.18 [-0.42, 0.06]
Heterogeneity: Tau2 = 0.15; Chi2 = 50.22, df = 15 (P <0.0001); I2 = 70%
Test for overall effect: Z = 1.50 (P = 0.13)
Footnotes
(1) Current pain intensity 0 to 100 mm VAS
(2) Muscle pain 0 to 10 for: 1) when waking, 2) chewing, 3) speaking, 4) at rest; score summed = 0 to 40 scale
(3) Current pain intensity 0 to 100 NRS (custom splint)
(4) Current pain intensity 0 to 100 NRS (prefabricated splint)
(5) Current maximum daily pain intensity 0 to 100 mm VAS
(6) 0 to 100 mm VAS; recorded 3 times daily with average calculated on weekly basis
(7) Current orofacial pain 0 to 100 NRS
(8) CPI 0 to 100 - SD is median value from range of SDs reported in the paper (prefabricated splint)
(9) CPI 0 to 100 - SD is median value from range of SDs reported in the paper (custom splint)
(10) Current pain intensity 0 to 100 VAS (splint vs control)
(11) Current pain intensity 0 to 100 VAS (splint + manipulative and physical therapies vs manipulative and physical therapies)
Table 1  Splint versus no/minimal treatment in TMD patients, outcome: Pain: any combinable scale (higher = more pain) – 0 to 3 months
194 BRITISH DENTAL JOURNAL  |  VOLUME 228  NO. 3  |  FEBRUARy 14 2020
RESEARCH
© The Author(s), under exclusive licence to British Dental Association 2020
the result when removing those trials that did 
not use the above diagnostic criteria: SMD 
-0.24 (95% CI -0.52 to 0.04; P = 0.09; I2 = 71%; 
851 participants).
We carried out a sensitivity analysis 
restricting the meta-analysis in Table  1 to 
studies that measured pain at the time of 
assessment (current pain) measured on a 0 to 
100 VAS or NRS. The results were consistent 
with the main SMD results: MD -4.48 (95% 
CI -11.59  to 2.64; P  =  0.22; I2  =  94%; 874 
participants).
We also carried out a sensitivity analysis 
restricting the meta-analysis in Table  1 to 
studies using stabilisation splints. Again, 
this did not change the result: SMD 0.04 
(95% CI -0.13  to 0.22; P  =  0.62; I2  =  27%; 
750 participants). This removed much of the 
heterogeneity seen in the other analyses.
Patients with bruxism
Only one of the studies focusing on patients 
with bruxism provided usable outcome data 
at 0 to 3 months;45 however, no studies looked 
at the primary outcome tooth wear. The 
aforementioned study on 78 patients looked 
at the other primary outcome pain on a 0 to 10 
scale and indicated that splints reduced pain 
MD -2.01 (95% CI -2.62, -1.40).
Discussion
Summary of main results
Despite the inclusion of 35 studies comparing 
oral splints to no splints or a minimal 
intervention in patients with TMD, the body 
of evidence was assessed as being at very low 
certainty (see Summary of findings table in 
online-only Supplementary Appendix  5). 
There was no evidence that oral splints 
improved the following outcomes: pain; 
clicking of the temporomandibular joint; 
restricted mouth opening; or quality of life. 
For patients with bruxism, there was 
insufficient evidence to conclude whether 
the provision of oral splints reduced tooth 
wear, as no studies reported this. Although 
a small number of studies reported pain and 
other outcomes, there was also insufficient 
evidence to conclude whether or not oral 
splints were beneficial. We were unable to 
undertake any sensitivity analyses due to the 
lack of outcome data.
For the TMD patients, we undertook three 
separate sensitivity analyses restricted to trials 
where: a) the inclusion criteria were based 
on, or could be clearly mapped to, specific 
pre-determined sets of diagnostic criteria; 
b) only stabilisation splints were used; and 
c) current pain was measured on a 0 to 100 
visual analogue scale or numerical rating 
scale. There were no differences in the results 
based on these factors.
For both patients with TMD and bruxism, 
due to differences in the diagnoses of the 
included trial participants and differences 
in the types of splints and control groups 
used, the applicability of the evidence is 
questionable and certainly incomplete for 
patients with bruxism.
Pain was reported in numerous different 
ways, at different times, and this reduced the 
number of studies that could be combined 
in a meta-analysis to produce a pooled 
estimate. The use of an agreed measure for 
pain and how and when this is measured 
would enable the pain data from all studies 
to contribute to a single pooled estimate. It 
is also important to consider what would be 
a clinically important reduction in pain. It 
is suggested that a reduction of around 20% 
represents a minimally important decrease, 
30% a moderately important decrease and 
50% a substantial decrease.48
Numerous studies reported on some of 
our outcomes but did not report the data 
in a suitable format for inclusion in our 
meta-analyses (including missing standard 
deviations). This can mean that meta-analyses 
are biased due to missing information. This 
highlights the need for standardisation in 
both ‘what to measure’ and ‘how to measure 
it’ in clinical trials within this area of research; 
otherwise, there will continue to be research 
waste, with data that we are unable to pool in 
data syntheses. Initiatives such as IMMPACT 
(Initiative on Methods, Measurement, and 
Pain Assessment in Clinical Trials), COMET 
(Core Outcome Measures in Effectiveness 
Trials) and COSMIN (COnsensus-based 
Standards for the selection of health 
Measurement INstruments) could help with 
these issues.
Certainty of the evidence
The certainty of the evidence for comparing 
splints with no splints/minimal interventions 
in patients with all sub-types of TMD was 
downgraded to ‘very low’ due to the studies 
being of high risk of bias, heterogeneity and 
lack of precision in the estimates (see online-
only Supplementary Appendix  5). Most 
studies were assessed as being at high risk 
of bias due to the inability of researchers to 
blind patients to wearing a splint or not. As 
the primary outcome for the TMD patients 
was pain assessed by the patients themselves, 
this meant that outcome measurement was 
also assessed as being at high risk of bias. This 
risk of bias does not necessarily reflect how 
well the studies have been conducted as it is 
not possible to design trials to overcome this 
problem. However, the bias should still be 
acknowledged when considering our overall 
certainty of the evidence. If blinding was to 
be disregarded, our certainty of the evidence 
would still remain low.
There were no studies looking at tooth wear, 
and very few studies and lack of useable other 
data for the patients with bruxism; therefore 
we were unable to determine whether splints 
were effective in these patients.
The risk of bias for all the studies was high. 
Although patient blinding is not possible 
when comparing oral splints with no splints 
or a minimal intervention, there were also 
problems with selective reporting bias and 
incomplete outcome data.
Alternative treatment options for TMD
Other recent research into treatment options 
for the management of TMD has included 
orthognathic surgery,49 TMJ lavage,50 
physiotherapy,51,52 low-level laser therapy,53,54 
exercise therapy,55 pharmacological treatment, 
56 and acupuncture. 57 However, results are 
mixed and generally unconvincing.
Conclusions
Implications for healthcare
From this systematic review, there is no clear 
evidence to support the provision of splints 
for the various sub-types of TMD or bruxism. 
However, the body of evidence that this 
conclusion is based on is of very low certainty. 
The studies included in this review differed 
in three important factors: 1) diagnoses, 2) 
splint type, and 3) outcome measurement/
reporting. This made it difficult to draw clear 
and definitive conclusions.
Recommendations for future research
Further well-conducted randomised 
controlled trials are urgently needed to 
determine whether the use of splints is 
clinically effective, generates meaningful 
patient benefit and whether splints offer an 
efficient use of resources in both Bruxism 
and TMD. Multiple trials will be required to 
concentrate on specific sub-types of TMD in 
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order to facilitate future, more focused meta-
analyses. The need for further trials is perhaps 
more pronounced in bruxism patients, as 
there were no trials measuring tooth wear.
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